Mankind Pharma demonstrates strong revenue growth, with sales increasing from ₹ 3,334 Cr in Mar 2015 to ₹ 12,207 Cr in Mar 2025. The compounded sales growth has been robust, with a 10-year CAGR of 14%, a 5-year CAGR of 16%, and a 3-year CAGR of 16%. The TTM sales growth is also strong at 18%. However, the compounded profit growth shows some deceleration, with a 10-year CAGR of 16%, a 5-year CAGR of 15%, and a 3-year CAGR of 13%. The TTM profit growth is 10%. The YOY profit growth shows a concerning trend, with a decline of 10% in Mar 2025. This indicates potential challenges in maintaining profitability despite strong revenue growth.

The Return on Capital Employed (ROCE) has fluctuated over the years. While specific ROCE data for Mar 2015 and Mar 2020 is unavailable, it was 37% in Mar 2021, 32% in Mar 2022, 22% in Mar 2023, 26% in Mar 2024 and 18% in Mar 2025. This decline in ROCE raises concerns about the efficiency with which the company is utilizing its capital. The Return on Equity (ROE) also reflects this trend, with a 5-year average of 21%, a 3-year average of 19%, and a Last Year value of 17%. This suggests a decreasing return on shareholder funds. The Cash Conversion Cycle has also lengthened from 82 days in Mar 2024 to 146 days in Mar 2025, potentially indicating less efficient working capital management.

Mankind Pharma's financial prudence is a concern, primarily due to a significant increase in borrowings. Total borrowings have surged from ₹ 170 Cr in Mar 2023 to ₹ 8,511 Cr in Mar 2025. This increase in debt could elevate financial risk. Interest payments have also increased substantially from ₹ 35 Cr in Mar 2024 to ₹ 429 Cr in Mar 2025. Despite consistent profitability, this level of debt increase could strain the company's financial stability. The dividend payout ratio has remained at 0% from Mar 2020 to Mar 2025, except for 24% in Mar 2021. This lack of consistent dividend payouts might be a concern for investors seeking regular income.

The shareholding pattern of Mankind Pharma indicates a strong promoter presence, although it has slightly decreased over the past year. Promoter holding has decreased from 74.88% in Mar 2024 to 72.70% in Mar 2025. The FII holding has increased from 9.87% in Mar 2024 to 12.92% in Mar 2025, and the DII holding has also slightly increased from 11.14% to 11.47% over the same period. This suggests growing institutional interest in the company. The number of shareholders has increased from 135,116 in Mar 2024 to 180,597 in Mar 2025, indicating an expanding investor base. Overall, the ownership structure remains relatively stable with increasing institutional participation.

There is no specific data available on off-balance sheet exposure quantification. Without this information, it's difficult to fully assess the company's financial risk related to potential liabilities or obligations not reflected on the balance sheet.

There is no specific data available on contingent liability evaluation. Without this information, it is challenging to evaluate potential risks arising from pending legal or regulatory actions.

There is no specific data available on foreign exchange or interest rate exposure, making it impossible to determine the company's vulnerability to fluctuations in currency exchange rates or interest rates.

There is no specific data available on regulatory compliance cost trends. Without this information, it is difficult to evaluate the potential impact of increasing regulatory burdens on the company's financials.